- $2.09bn
- $1.98bn
- $225.21m
AxoGen's prelim Q4 revenue beats expectations on strong portfolio performance
U.S. STOCKS ON THE MOVE-Raymond James, CAVA, Paramount Skydance
U.S. STOCKS ON THE MOVE-Meta, GE Vernova, Kroger
U.S. STOCKS ON THE MOVE-Salesforce, Dollar General, gold miners
Axogen rises after FDA approves co's nerve repair graft
FDA approves Axogen's nerve repair graft (updated)
FDA approves Axogen's nerve repair graft
U.S. RESEARCH ROUNDUP-Air Products, Hanover Insurance, Kinsale Capital
U.S. RESEARCH ROUNDUP- Alphabet, Boeing, KLA
Medical device maker AxoGen beats Q3 revenue expectations, hikes FY view
U.S. STOCKS ON THE MOVE-Artelo Biosciences, Coya, Vital Energy
U.S. STOCKS ON THE MOVE-Artelo Biosciences, Coya, Vital Energy
Axogen slips as FDA delays nerve graft application
U.S. STOCKS ON THE MOVE-Verint Systems, Intel, China ADR
Axogen slips as FDA delays nerve graft application
AxoGen Inc reports results for the quarter ended June 30 - Earnings Summary
AxoGen Q2 revenue up 18.3%, beats estimates
U.S. RESEARCH ROUNDUP-Brighthouse Financial, Payoneer Global, Voya Financial
AxoGen Inc reports results for the quarter ended March 31 - Earnings Summary